Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Irreversible antagonist

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Irreversible antagonist. Displaying page 1 of 1.
    EudraCT Number: 2013-001057-27 Sponsor Protocol Number: CCD-1207-PR-0091 Start Date*: 2014-01-24
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A 52-week, double-blind, randomized, multinational, multicentre, 2-arm parallel-group, active-controlled clinical trial of fixed combination of beclometasone dipropionate plus formoterol fumarate p...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) HU (Completed) DE (Completed) IT (Completed) CZ (Completed) SK (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-004405-41 Sponsor Protocol Number: CLI-05993BA1-02 Start Date*: 2018-09-06
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A phase II, multicentre, randomised, double-blind, double-dummy, active-controlled, 3-way cross-over study to evaluate the efficacy of CHF 5993 administered via Dry Powder Inhaler (DPI) versus CHF ...
    Medical condition: chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) BG (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000063-91 Sponsor Protocol Number: CCD-1208-PR-0090 Start Date*: 2013-11-26
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A 52-week, Double Blind, Double dummy, Randomized, Multinational, Multicentre, 3-arm Parallel Group, active Controlled Clinical Trial of fixed combination of beclometasone dipropionate plus formote...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed) GB (Completed) SK (Completed) BG (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2010-020440-35 Sponsor Protocol Number: D589BC00004 Start Date*: 2011-09-16
    Sponsor Name:Imperial College London
    Full Title: GR activity in induced sputum macrophages, and a change in inflammatory biomarkers 2-hours after a single dose of either Symbicort®/Budesonide/Formoterol or placebo in Chronic Obstructive Pulmonary...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001704-22 Sponsor Protocol Number: CCD-05993AA1-08 Start Date*: 2015-02-25
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A 52-week, Double Blind, Double dummy, Randomized, Multinational, Multicentre, 2-arm Parallel Group, active Controlled Clinical Trial of fixed combination of beclometasone dipropionate plus formote...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) PT (Completed) HU (Completed) CZ (Completed) RO (Completed) DK (Completed) DE (Completed) AT (Completed) NO (Completed) PL (Completed) FR (Completed) BG (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000053-21 Sponsor Protocol Number: FLUI-2014-134 Start Date*: 2015-05-05
    Sponsor Name:FLUIDDA nv
    Full Title: Placebo controlled study to assess the effect of Roflumilast in hyperinflated COPD patients in addition to LABA/LAMA therapy using Functional Respiratory Imaging.
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003780-38 Sponsor Protocol Number: P05575 Start Date*: 2009-10-27
    Sponsor Name:Schering-Plough Research Institute
    Full Title: A 2-Year, Dose Range-Finding, Adaptive-Design Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD
    Medical condition: COPD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) CZ (Prematurely Ended) SK (Completed) GR (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004297-98 Sponsor Protocol Number: 117113 Start Date*: 2014-09-01
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study 117113: Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients characterized by eosinophil level.
    Medical condition: Treatment of severe Chronic Obstructive Pulmonary Disease (COPD) in patients presenting frequent exacerbations
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SK (Completed) DE (Completed) GB (Completed) DK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2018-003197-28 Sponsor Protocol Number: CQBW251B2201 Start Date*: 2019-08-02
    Sponsor Name:Novartis Pharma AG
    Full Title: A 24-week multi-center, double-blind, placebo controlled dose range finding study to investigate the efficacy and safety of oral QBW251 in COPD patients on triple inhaled therapy (LABA/LAMA/ICS)
    Medical condition: Chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10029972 Obstructive airways disease (chronic) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) NL (Completed) BE (Completed) DK (Completed) FR (Completed) AT (Completed) CZ (Completed) GR (Completed) HU (Completed) IT (Completed) ES (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-001487-35 Sponsor Protocol Number: CCD-05993AA1-07 Start Date*: Information not available in EudraCT
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A Multinational, Multicentre, Randomised, Open-Label, Active-Controlled, 26-Week, 2-Arm, Parallel Group Study to Evaluate the Non-Inferiority of Fixed Combination of Beclometasone Dipropionate Plus...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) LT (Completed) NL (Completed) HU (Completed) DE (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004298-28 Sponsor Protocol Number: MEA117106 Start Date*: 2014-05-02
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study MEA117106: Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients.
    Medical condition: Treatment of severe Chronic Obstructive Pulmonary Disease (COPD) in patients presenting frequent exacerbations
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) PL (Completed) IT (Completed) BE (Completed) ES (Completed) EE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002452-13 Sponsor Protocol Number: HZC115151 Start Date*: 2012-01-10
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhale...
    Medical condition: Subjects with Chronic Obstructive Pulmonary Disease (COPD).
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004041-17 Sponsor Protocol Number: XEN-D0501-CL-05 Start Date*: 2013-12-13
    Sponsor Name:Xention Limited
    Full Title: A double-blind, randomised, placebo-controlled, crossover study to assess the efficacy of XEN-D0501, a TRPV1 antagonist, in reducing the frequency of cough in patients with chronic obstructive pulm...
    Medical condition: Chronic Obstructive Pulmonary Disease.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000558-40 Sponsor Protocol Number: CCD-06302AA1-01 Start Date*: 2016-03-02
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A multicenter, randomised, double blind, placebo-controlled, incomplete block, 3-way cross-over study to evaluate the efficacy and safety of 4 doses of glycopyrronium bromide DPI in moderate to sev...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2013-005268-25 Sponsor Protocol Number: CCD-05993AA1-09 Start Date*: 2014-08-01
    Sponsor Name:CHIESI FARMACEUTICI SPA
    Full Title: A MULTINATIONAL, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED , 2-WAY CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GLYCOPYRROLATE BROMIDE ADMINISTERED VIA PMDI (CHF 5259), FO...
    Medical condition: CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-001818-38 Sponsor Protocol Number: EFC16750 Start Date*: 2021-03-02
    Sponsor Name:Sanofi-Aventis Recherche & Developpement
    Full Title: Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with mode...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    26.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001953-28 Sponsor Protocol Number: EFC15804 Start Date*: 2019-07-01
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstr...
    Medical condition: Chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) DK (Completed) FI (Completed) CZ (Completed) HU (Completed) PL (Completed) SK (Completed) BG (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 08:27:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA